Johnson & Johnson fined in France for smearing rivals

France’s competition enforcer has fined Johnson & Johnson subsidiary Janssen-Cilag €25 million after finding the company delayed the availability of low-cost generic versions of one of its painkillers, through both pressure on pharmaceutical regulators and a disparaging and misleading marketing campaign.

Unlock unlimited access to all Global Competition Review content